Evidence-based investigations and treatments of recurrent pregnancy loss

被引:195
作者
Christiansen, OB
Andersen, AMN
Bosch, E
Daya, S
Delves, PJ
Hviid, TV
Kutteh, WH
Laird, SM
Li, TC
van der Ven, K
机构
[1] Rigshosp, Fertil Clin 4071, DK-2100 Copenhagen, Denmark
[2] Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark
[3] Univ Copenhagen, Inst Social Med, Copenhagen, Denmark
[4] Inst Valenciano Infertil, Valencia, Spain
[5] McMaster Univ, Dept Obstet & Gynecol, Hamilton, ON, Canada
[6] UCL, Div Infect & Immun, Dept Immunol & Mol Pathol, London, England
[7] Sheffield Hallam Univ, Div Biomed Sci, Sheffield S1 1WB, S Yorkshire, England
[8] Jessop Hosp Women, Biomed Res Unit, Sheffield, S Yorkshire, England
[9] Univ Tennessee, Dept Obstet & Gynecol, Div Reprod Endocrinol & Immunol, Memphis, TN USA
[10] Univ Bonn, Dept Obstet & Gynaecol, IVF Clin, D-5300 Bonn, Germany
关键词
abortion; anticardiolipin; HLA-G; recurrent miscarriage; uterine fibroids; recurrent pregnancy loss;
D O I
10.1016/j.fertnstert.2004.12.018
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To give an overview of currently used investigations and treatments offered to women with recurrent pregnancy loss (RPL) and, from an evidence-based point of view, to evaluate the usefulness of these interventions. Design: Ten experts on epidemiologic, genetic, anatomic, endocrinologic, thrombophilic, immunologic, and immunogenctic aspects of RPL discussed methodologic problems threatening the validity of research in RPL during and after an international workshop on the evidence-based management of RPL. Conclusion(s): Most RPL patients have several risk factors for miscarriage, and an extensive investigation for all major factors should always be undertaken. There is an urgent need for agreement concerning the thresholds for detecting what is normal and abnormal, irrespective of whether laboratory tests or uterine abnormalities are concerned. A series of lifestyle factors should be reported in future studies of RPL because they might modify the effect of laboratory or anatomic risk factors. More and larger randomized controlled trials, including trials of surgical procedures, are urgently needed, and to achieve this objective multiple centers have to collaborate. Current meta-analyses evaluating the efficacy of treatments of RPL are generally pooling very heterogeneous patient populations and treatments. It is recommended that future meta-analyses look at subsets of patients and treatment protocols that are more combinable. (Fertil Steril (R) 2005;83:821-39. (c) 2005 by American Society for Reproductive Medicine.).
引用
收藏
页码:821 / 839
页数:19
相关论文
共 154 条
[1]   A FOLLOW-UP-STUDY OF IMMUNOGLOBULIN LEVELS AND AUTOBODIES IN AN UNSELECTED PREGNANT POPULATION [J].
AILUS, KT .
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1994, 31 (04) :189-196
[2]   HLA-G genotypes and pregnancy outcome in couples with unexplained recurrent miscarriage [J].
Aldrich, CL ;
Stephenson, MD ;
Karrison, T ;
Odem, RR ;
Branch, DW ;
Scott, JR ;
Schreiber, JR ;
Ober, C .
MOLECULAR HUMAN REPRODUCTION, 2001, 7 (12) :1167-1172
[3]  
Alexander S, 1988, EARLY PREGNANCY LOSS, P355
[4]   Regulatory T cells mediate maternal tolerance to the fetus [J].
Aluvihare, VR ;
Kallikourdis, M ;
Betz, AG .
NATURE IMMUNOLOGY, 2004, 5 (03) :266-271
[5]   Long term follow-up of patients with polycystic ovarian syndrome after laparoscopic ovarian drilling: clinical outcome [J].
Amer, SAK ;
Gopalan, V ;
Li, TC ;
Ledger, WL ;
Cooke, ID .
HUMAN REPRODUCTION, 2002, 17 (08) :2035-2042
[6]   Clinical transplantation tolerance: The promise and challenges [J].
Ansari, MJI ;
Sayegh, MH .
KIDNEY INTERNATIONAL, 2004, 65 (05) :1560-1563
[7]   Detection of soluble HLA-G levels in maternal serum can be predictive for a successful pregnancy [J].
Athanassakis, I ;
Paflis, M ;
Ranella, A ;
Vassiliadis, S .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (04) :1834-1837
[8]   VALIDATION OF QUESTIONNAIRE REPORTED MISCARRIAGE, MALFORMATION AND BIRTH-WEIGHT [J].
AXELSSON, G ;
RYLANDER, R .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1984, 13 (01) :94-98
[9]   Fibroids, infertility and pregnancy wastage [J].
Bajekal, N ;
Li, TC .
HUMAN REPRODUCTION UPDATE, 2000, 6 (06) :614-620
[10]  
Barakonyi A, 1999, AM J REPROD IMMUNOL, V42, P83